Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma (Q97568608)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32669548%20AND%20SRC:MED&resulttype=core&format=json

20 July 2020

title

Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32669548%20AND%20SRC:MED&resulttype=core&format=json

20 July 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32669548%20AND%20SRC:MED&resulttype=core&format=json

20 July 2020

Farzana Pashankar

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32669548%20AND%20SRC:MED&resulttype=core&format=json

20 July 2020

Shoba A Navai

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32669548%20AND%20SRC:MED&resulttype=core&format=json

20 July 2020

Stephen Gottschalk

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32669548%20AND%20SRC:MED&resulttype=core&format=json

20 July 2020

Nabil Ahmed

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32669548%20AND%20SRC:MED&resulttype=core&format=json

20 July 2020

22

Malcolm K Brenner

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32669548%20AND%20SRC:MED&resulttype=core&format=json

20 July 2020

21

Helen E Heslop

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32669548%20AND%20SRC:MED&resulttype=core&format=json

20 July 2020

19

Adrian Gee

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32669548%20AND%20SRC:MED&resulttype=core&format=json

20 July 2020

18

Bambi Grilley

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32669548%20AND%20SRC:MED&resulttype=core&format=json

20 July 2020

20

Gianpietro Dotti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32669548%20AND%20SRC:MED&resulttype=core&format=json

20 July 2020

16

Olga Dakhova

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32669548%20AND%20SRC:MED&resulttype=core&format=json

20 July 2020

10

Claudia Gerken

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32669548%20AND%20SRC:MED&resulttype=core&format=json

20 July 2020

15

Birju Mehta

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32669548%20AND%20SRC:MED&resulttype=core&format=json

20 July 2020

14

Ankita Shree

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32669548%20AND%20SRC:MED&resulttype=core&format=json

20 July 2020

2

Sujith K Joseph

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32669548%20AND%20SRC:MED&resulttype=core&format=json

20 July 2020

7

Tiara T Byrd

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32669548%20AND%20SRC:MED&resulttype=core&format=json

20 July 2020

4

Christopher DeRenzo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32669548%20AND%20SRC:MED&resulttype=core&format=json

20 July 2020

23

Winfried S Wels

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32669548%20AND%20SRC:MED&resulttype=core&format=json

20 July 2020

11

Mamta Kalra

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32669548%20AND%20SRC:MED&resulttype=core&format=json

20 July 2020

author name string

Khaled Sanber

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32669548%20AND%20SRC:MED&resulttype=core&format=json

20 July 2020

John Hicks

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32669548%20AND%20SRC:MED&resulttype=core&format=json

20 July 2020

Mina L Xu

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32669548%20AND%20SRC:MED&resulttype=core&format=json

20 July 2020

Catherine Robertson

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32669548%20AND%20SRC:MED&resulttype=core&format=json

20 July 2020

Huimin Zhang

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32669548%20AND%20SRC:MED&resulttype=core&format=json

20 July 2020

Vita S Salsman

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32669548%20AND%20SRC:MED&resulttype=core&format=json

20 July 2020

publication date

15 July 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32669548%20AND%20SRC:MED&resulttype=core&format=json

20 July 2020

published in

Nature Communications

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32669548%20AND%20SRC:MED&resulttype=core&format=json

20 July 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32669548%20AND%20SRC:MED&resulttype=core&format=json

20 July 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32669548%20AND%20SRC:MED&resulttype=core&format=json

20 July 2020

page(s)

3549

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32669548%20AND%20SRC:MED&resulttype=core&format=json

describes a project that uses

20 July 2020

Cytoscape

1 reference

9 June 2022

https://europepmc.org/search?query=(METHODS:'Cytoscape')

inferred from PubMed Central ID database lookup

cites work

Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

Rhabdomyosarcoma, Ewing Sarcoma, and Other Round Cell Sarcomas

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

Statistical analysis of CDR3 length distributions for the assessment of T and B cell repertoire biases.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

T cell receptor CDR3 loop length repertoire is determined primarily by features of the V(D)J recombination reaction

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

A Systems Biology Approach Identifies FUT8 as a Driver of Melanoma Metastasis.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

AKT/PKB Signaling: Navigating the Network

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

Pediatric rhabdomyosarcoma with bone marrow metastasis

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

CAR T cell therapy: inroads to response and resistance

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

Neoantigens in cancer immunotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

T cell receptor next-generation sequencing reveals cancer-associated repertoire metrics and reconstitution after chemotherapy in patients with hematological and solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

USP2a Supports Metastasis by Tuning TGF-β Signaling.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

PD-L1 assessment in pediatric rhabdomyosarcoma: a pilot study.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

Expression of HER2/erbB-2 correlates with survival in osteosarcoma

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021

Using synthetic templates to design an unbiased multiplex PCR assay.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-020-17175-8

7 January 2021